Dr. Gotto is a Urologic Oncologist and Clinical Associate Professor in the Departments of Surgery and Oncology at the University of Calgary. He completed his undergraduate and residency training at the University of British Columbia and went on to complete his Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York and his Masters of Public Health at Harvard. Dr. Gotto specializes in the management of prostate, bladder, and kidney cancer. He is a member of the Medical Advisory Board for Kidney Cancer Canada. He is the Medical Director of the Clinic for Advanced and Metastatic Prostate Cancer (CAMP) at the Calgary Prostate Cancer Centre and is the Principal Investigator for a number of clinical trials in advanced prostate cancer. He has been named one of Calgary’s Top 40 under 40.
Biography
Area of Focus
Summary of Research
- Woon DTS, Chandrasekar T, Aaron L, Basappa NS, Chi KN, Conter HJ, Gotto G, Hotte SJ, Malone S, Saad F, Shayegan B, Park-Wyllie L, Hamilton RJ. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. Can Urol Assoc J. 2018 Oct;12(10):328-336. doi:
10.5489/cuaj.5378. Epub 2018 Jul 16. PubMed PMID: 29688882; PubMed Central PMCID:PMC6192749. - Athanazio D, Gotto G, Shea-Budgell M, Yilmaz A, Trpkov K. Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade. Histopathology. 2017 Jun;70(7):1098-1106. doi: 10.1111/his.13179. Epub 2017 Mar 28. PubMed PMID: 28370140.
- Gotto GT, Shea-Budgell MA, Dean Ruether J. Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta. Can Urol Assoc J. 2016 Jan-Feb;10(1-2):33-8. doi: 10.5489/cuaj.3143. PubMed PMID: 26977204; PubMed Central PMCID: PMC4771556.
- Gotto GT, Shea-Budgell MA, Rose MS, Ruether JD. Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time. Can Urol Assoc J. 2015 Jul-Aug;9(7-8):236-41. doi: 10.5489/cuaj.2722. PubMed PMID: 26316905; PubMed Central PMCID: PMC4537332.
- Gotto GT, Yu C, Bernstein M, Eastham JA, Kattan MW. Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer. Front Oncol. 2014 Oct 27;4:296.doi: 10.3389/fonc.2014.00296. eCollection 2014. PubMed PMID: 25386410; PubMed Central PMCID: PMC4209823.
- Sandhu JS, Gotto GT, Herran LA, Scardino PT, Eastham JA, Rabbani F. Age, obesity, medical comorbidities and surgical technique are predictive of symptomatic anastomotic strictures after contemporary radical prostatectomy. J Urol. 2011 Jun;185(6):2148-52. doi: 10.1016/j.juro.2011.02.003. Epub 2011 Apr 15. PubMed PMID: 21496848.
- Gotto GT, Yunis LH, Vora K, Eastham JA, Scardino PT, Rabbani F. Impact of prior prostate radiation on complications after radical prostatectomy. J Urol. 2010 Jul;184(1):136-42. doi: 10.1016/j.juro.2010.03.031. Epub 2010 May 15. PubMed PMID: 20478594.
Area Of Focus
Summary Of Research
- Woon DTS, Chandrasekar T, Aaron L, Basappa NS, Chi KN, Conter HJ, Gotto G, Hotte SJ, Malone S, Saad F, Shayegan B, Park-Wyllie L, Hamilton RJ. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. Can Urol Assoc J. 2018 Oct;12(10):328-336. doi:
10.5489/cuaj.5378. Epub 2018 Jul 16. PubMed PMID: 29688882; PubMed Central PMCID:PMC6192749. - Athanazio D, Gotto G, Shea-Budgell M, Yilmaz A, Trpkov K. Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade. Histopathology. 2017 Jun;70(7):1098-1106. doi: 10.1111/his.13179. Epub 2017 Mar 28. PubMed PMID: 28370140.
- Gotto GT, Shea-Budgell MA, Dean Ruether J. Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta. Can Urol Assoc J. 2016 Jan-Feb;10(1-2):33-8. doi: 10.5489/cuaj.3143. PubMed PMID: 26977204; PubMed Central PMCID: PMC4771556.
- Gotto GT, Shea-Budgell MA, Rose MS, Ruether JD. Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer and changes in practice over time. Can Urol Assoc J. 2015 Jul-Aug;9(7-8):236-41. doi: 10.5489/cuaj.2722. PubMed PMID: 26316905; PubMed Central PMCID: PMC4537332.
- Gotto GT, Yu C, Bernstein M, Eastham JA, Kattan MW. Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer. Front Oncol. 2014 Oct 27;4:296.doi: 10.3389/fonc.2014.00296. eCollection 2014. PubMed PMID: 25386410; PubMed Central PMCID: PMC4209823.
- Sandhu JS, Gotto GT, Herran LA, Scardino PT, Eastham JA, Rabbani F. Age, obesity, medical comorbidities and surgical technique are predictive of symptomatic anastomotic strictures after contemporary radical prostatectomy. J Urol. 2011 Jun;185(6):2148-52. doi: 10.1016/j.juro.2011.02.003. Epub 2011 Apr 15. PubMed PMID: 21496848.
- Gotto GT, Yunis LH, Vora K, Eastham JA, Scardino PT, Rabbani F. Impact of prior prostate radiation on complications after radical prostatectomy. J Urol. 2010 Jul;184(1):136-42. doi: 10.1016/j.juro.2010.03.031. Epub 2010 May 15. PubMed PMID: 20478594.